About the Bourgoin site:
Thermo Fisher Scientific’s facility in Bourgoin, France has been supporting the pharmaceutical industry for 60+ years. It is an FDA-approved center of excellence specializing in the early and late-stage development and commercial manufacturing of oral solid dose (OSD) products, with a particular focus on high-potency active pharmaceutical ingredients (APIs).
Thermo Fisher Scientific’s facility in Bourgoin, France has been supporting the pharmaceutical industry for 60+ years. It is an FDA-approved center of excellence specializing in the early and late-stage development and commercial manufacturing of oral solid dose (OSD) products, with a particular focus on high-potency active pharmaceutical ingredients (APIs).
Early development hub:
Our new 430-square-meter dedicated R&D hub is equipped with state-of-the-art technologies and equipment. It supports formulation development and mature product characterization for oral solid dose forms. This empowers our clients to accelerate their timelines through informed decision-making, reduced experimental efforts, and minimized development risks.
Key areas of expertise:
- Early-stage development and manufacturing of oral solid dose products
- Expert handling of highly potent APIs up to category 3B, including cytostatic
- Comprehensive packaging solutions (bottles, blisters, high-speed lines)
- Seamless transfer and global commercialization of development projects
- Manufacturing capabilities for tablets, capsules, powders, and granules
- Specialized support for orphan/niche and pediatric indication products
- Small-scale through large-scale commercial supply capabilities
